Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Meredith R.N. Waring
Observed name:
Meredith Waring
Institution:
University of Colorado Anschutz
Observed institution:
University of Colorado Anschutz
ORCID:
0009-0000-2955-8989
Observed ORCID:
0009-0000-2955-8989
OpenAlex ID:
A5089402696
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
·
Clinical Cancer Research
·
14
Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
2020
·
Christopher Hanyoung Lieu
, Sarah Lindsey Davis
, et al.
·
Journal of Clinical Oncology
·
9
A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellite-stable, refractory, metastatic colorectal cancer (mCRC).
2022
·
Tyler Friedrich
, Patrick Jud Blatchford
, et al.
·
Journal of Clinical Oncology
·
8
Supplementary Figure S2 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S1 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S4 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S3 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S6 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Data from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S2 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S4 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Figure S8 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Supplementary Table S1 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Data from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
2024
·
Robert W. Lentz
, Tyler J. Friedrich
, et al.
Show more works
View as search
Works count:
17
Citation count:
31
H-index:
3
I10-index:
1
Year
Topic
Type